iBody Inc. is a start-up company launched from Nagoya University, Japan, at Feb 2018.
We have pioneered a unique technology of discovering, generating, and producing monoclonal antibodies from single B cells.
Our mission is to contribute human healthcare by lightning monoclonal antibody development.
102 Incubation Facility, Nagoya University,
1 Furo-cho, Chikusa-ku, Nagoya, Aichi 464-0814, JAPAN
Feb. 1st, 2018
CEO Yo Amakusa
CSO Shoji Ohuchi Ph.D.
Yoshihiro Kakeji Ph.D. (Professor, Kobe University)
Shun'ichi Kuroda Ph.D. (Professor, Osaka University)
Kouhei Tsumoto Ph.D. (Professor, The University of Tokyo)